Switch theme
Sign up to access all valuation multiples
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
2013
32
LTM Revenue $42.8M
LTM EBITDA n/a
-$9.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spero Therapeutics has a last 12-month revenue of $42.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Spero Therapeutics achieved revenue of $27.4M and an EBITDA of -$72.5M.
Spero Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spero Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $96.7M | $27.4M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | $25.8M | -$72.5M | XXX | XXX | XXX |
| EBITDA Margin | 27% | -265% | XXX | XXX | XXX |
| Net Profit | -$46.4M | $22.8M | XXX | XXX | XXX |
| Net Margin | -48% | 83% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Spero Therapeutics's stock price is $1.
Spero Therapeutics has current market cap of $39.2M, and EV of -$9.4M.
See Spero Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$9.4M | $39.2M | XXX | XXX | XXX | XXX | $-1.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Spero Therapeutics has market cap of $39.2M and EV of -$9.4M.
Spero Therapeutics's trades at -0.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Spero Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Spero Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$9.4M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSpero Therapeutics's NTM/LTM revenue growth is -49%
Spero Therapeutics's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $3.1M for the same period.
Over next 12 months, Spero Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Spero Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Spero Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -72% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -265% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -381% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -314% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 87% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 353% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 365% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spero Therapeutics acquired XXX companies to date.
Last acquisition by Spero Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Spero Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Spero Therapeutics founded? | Spero Therapeutics was founded in 2013. |
| Where is Spero Therapeutics headquartered? | Spero Therapeutics is headquartered in United States of America. |
| How many employees does Spero Therapeutics have? | As of today, Spero Therapeutics has 32 employees. |
| Who is the CEO of Spero Therapeutics? | Spero Therapeutics's CEO is Mr. Satyavrat Shukla, C.F.A.. |
| Is Spero Therapeutics publicy listed? | Yes, Spero Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Spero Therapeutics? | Spero Therapeutics trades under SPRO ticker. |
| When did Spero Therapeutics go public? | Spero Therapeutics went public in 2017. |
| Who are competitors of Spero Therapeutics? | Similar companies to Spero Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Spero Therapeutics? | Spero Therapeutics's current market cap is $39.2M |
| What is the current revenue of Spero Therapeutics? | Spero Therapeutics's last 12-month revenue is $42.8M. |
| What is the current EV/Revenue multiple of Spero Therapeutics? | Current revenue multiple of Spero Therapeutics is -0.2x. |
| What is the current revenue growth of Spero Therapeutics? | Spero Therapeutics revenue growth between 2023 and 2024 was -72%. |
| Is Spero Therapeutics profitable? | Yes, Spero Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
